Short Interest in Ipsen S.A. (OTCMKTS:IPSEY) Increases By 750.0%

Ipsen S.A. (OTCMKTS:IPSEY) saw a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,700 shares, an increase of 750.0% from the November 15th total of 200 shares. Based on an average daily trading volume, of 2,700 shares, the days-to-cover ratio is presently 0.6 days.

Ipsen Stock Down 1.4 %

Shares of Ipsen stock opened at $28.65 on Friday. The stock’s fifty day moving average is $29.87 and its 200 day moving average is $30.22. Ipsen has a one year low of $27.00 and a one year high of $34.06.

Analyst Ratings Changes

Separately, Royal Bank of Canada raised shares of Ipsen from a “hold” rating to a “moderate buy” rating in a report on Monday, September 16th.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.